The role of Helicobacter pylori infectious bacteria in people's disease and its treatment
Abstract
Background and purpose: Helicobacter pylori is a type of bacteria that can cause infection in the stomach and duodenum and also cause digestive problems and diseases such as stomach ulcers, stomach infections, gastritis and in severe cases even stomach cancer. About 50% of the world's population is infected with this microbe, and the rate of infection is the same in men and women. In Iran, the prevalence rate in the age group over 45 years is 75.6 and in the 19-45 years age group is 68%.
Research method: This research is a review article and based on library study and literature review, which were studied by studying the articles published in domestic and foreign journals regarding the prevalence of Helicobacter pylori infection in patients. In order to access articles related to the subject of research from domestic and international databases such as IranMedex, IranDoc, Medline, Cochrane, Embase, SID, Medlib, Pubmed, Web of Sciences, Science Direct, Magiran without time limit until 1401 with The use of standard keywords were searched and then relevant information was extracted and evaluated.
Findings: In this review, 14 studies were examined and the findings show that Helicobacter pylori is the cause of most cases of stomach ulcers and causes the occurrence of some gastrointestinal cancers and is the most important cause of stomach cancer and MALT lymphoma. is also considered.
Conclusion: According to the results, stomach biopsy culture and determination of antibiotic sensitivity of bacteria have been proposed as the best treatment method for stomach microbe infection. Considering the complications caused by long-term and chronic Helicobacter pylori infection in people who have a history of stomach cancer in their family members, the infection of this bacterium is very dangerous and it is necessary to completely eradicate it in these people, and this issue is only through tissue sample culture Stomach can be done.
Downloads
References
[2] S. Iravani, A. Naimi, P. Azimzadeh, and S. Solali, "Association of Helicobacter Pylori Infection with ABO and Rh blood groups in military students and soldiers," ISMJ, vol. 20, no. 3, pp. 308-316, 2017.
[3] F. Azizi, H. Hatami, and M. Janghorbani, "Epidemiology and control of common diseases in Iran," Tehran: Eshtiagh Publications, pp. 602-16, 2000.
[4] A. Mueller, S. Falkow, and M. R. Amieva, "Helicobacter pylori and gastric cancer: what can be learned by studying the response of gastric epithelial cells to the infection?," Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 8, pp. 1859-1864, 2005.
[5] M. A. Hedayati and S. Salavati, "Transcriptional profile of helicobacter pylori virulence genes in patients with gastritis and gastric cancer," Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2021, 2021.
[6] J. K. Hooi et al., "Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis," Gastroenterology, vol. 153, no. 2, pp. 420-429, 2017.
[7] A. Ganjali and A. Bahari, "An unexplored triangle: Helicobacter pylori Infection, Inflammation and Gastric Cancer," Iranian Journal of Cancer Care (ijca), vol. 2, no. 2, pp. 62-73, 2021.
[8] J. Yazdani-Charati, G. Janbabaei, S. Etemadinejad, S. Sadeghi, and F. Haghighi, "Survival of patients with stomach adenocarcinoma in North of Iran," Gastroenterology and hepatology from bed to bench, vol. 7, no. 4, p. 211, 2014.
[9] A. Goddard and R. Logan, "Diagnostic methods for Helicobacter pylori detection and eradication," British journal of clinical pharmacology, vol. 56, no. 3, pp. 273-283, 2003.
[10] M. Keramati, Z. Siadat, and M. Mahmoudi, "The correlation between H. pylori infection with serum ferritin concentration and iron deficiency anemia," International Journal of Hematology and Oncology, vol. 32, no. 1, pp. 016-020, 2007.
[11] N. Iqbal and N. Iqbal, "Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications," Molecular biology international, vol. 2014, 2014.
[12] G. Ingravallo et al., "CDX2 hox gene product in a rat model of esophageal cancer," Journal of Experimental & Clinical Cancer Research, vol. 28, pp. 1-6, 2009.
[13] C. Dunne, B. Dolan, and M. Clyne, "Factors that mediate colonization of the human stomach by Helicobacter pylori," World journal of gastroenterology, vol. 20, no. 19, pp. 5610-5624, 2014.
[14] J. P. Gisbert, "Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review," Therapeutic Advances in Gastroenterology, vol. 13, p. 1756284820968736, 2020.
[15] W. Fischbach, P. Malfertheiner, J. C. Hoffmann, W. Bolten, M. Kist, and S. Koletzko, "Helicobacter pylori and gastroduodenal ulcer disease," Deutsches Ärzteblatt International, vol. 106, no. 49, p. 801, 2009.
[16] I. M. Abu-Reida, R. M. Jamous, and M. S. Ali-Shtayeh, "Phytochemistry, pharmacological properties and industrial applications of Rhus coriaria L.(sumac)," Jordan journal of biological sciences, vol. 147, no. 1573, pp. 1-12, 2014.
[17] E. Braunwald, "Departments, divisions and centers in the evolution of medical schools," The American journal of medicine, vol. 119, no. 6, pp. 457-462, 2006.
[18] L. Monteiro, N. Gras, R. Vidal, J. Cabrita, and F. Mégraud, "Detection of Helicobacter pylori DNA in human feces by PCR: DNA stability and removal of inhibitors," Journal of Microbiological Methods, vol. 45, no. 2, pp. 89-94, 2001.
[19] M. J. Sharman, "Helicobacter: an exploration of therapeutics, homeostatic mechanisms and the application of the novel diagnostic technique, confocal endomicroscopy," University of Melbourne, Faculty of Veterinary and Agricultural Sciences, 2015.
[20] T. Horemans, "A quest for novel therapeutic and diagnostic approaches in Helicobacter pylori infections," University of Antwerp, 2014.
[21] E. J. Goldstein and J. V. Solnick, "Clinical significance of Helicobacter species other than Helicobacter pylori," Clinical infectious diseases, vol. 36, no. 3, pp. 349-354, 2003.
[22] F. Pakodi, O. M. Abdel-Salam, A. Debreceni, and G. Mózsik, "Helicobacter pylori. One bacterium and a broad spectrum of human disease! An overview," Journal of Physiology-Paris, vol. 94, no. 2, pp. 139-152, 2000.
[23] F. Franceschi et al., "Role of Helicobacter pylori infection on nutrition and metabolism," World journal of gastroenterology: WJG, vol. 20, no. 36, p. 12809, 2014.
[24] T. L. Cover and M. J. Blaser, "Helicobacter pylori in health and disease," Gastroenterology, vol. 136, no. 6, pp. 1863-1873, 2009.
[25] A. Z. Ables, I. Simon, and E. R. Melton, "Update on Helicobacter pylori treatment," American family physician, vol. 75, no. 3, pp. 351-358, 2007.
[26] R. McLoughlin, I. Racz, M. Buckley, H. J. O'Connor, and C. O'Morain, "Therapy of Helicobacter pylori," Helicobacter, vol. 9, pp. 42-48, 2004.
[27] H. D. Langtry and M. I. Wilde, "Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs," Drugs, vol. 56, pp. 447-486, 1998.
[28] X.-H. Huo et al., "Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients," World Journal of Gastroenterology: WJG, vol. 12, no. 19, p. 3105, 2006.
[29] N. Gholinia, A. A. Shafikhani, and A. Hajiaghamohammadi, "Comparing Regimens Based on Clarithromycin, Furazolidone, and Levofloxacin in Patients With Helicobacter Pylori Infection: A Clinical Trial," International Journal of Enteric Pathogens, vol. 9, no. 1, pp. 15-20, 2021.
[30] S. Alihosseini, R. Ghotaslou, F. S. Heravi, Z. Ahmadian, and H. E. Leylabadlo, "Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran," Journal of Chemotherapy, vol. 32, no. 6, pp. 273-285, 2020.
Copyright (c) 2023 Advances in Applied NanoBio-Technologies
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
